GNRH1 and osteoporosis: Among the 253 patients who completed the study, no differences in demographic characteristics between treatment CAB (n = 196) and GnRH (n = 57) groups were observed including occurrence of osteoporosis-related concurrent disease (p > 0.05, Table 1 and Supplementary Table 1); except for their prostate volume (52.09cc in CAB group vs. 38.84cc in GnRH group), clinical N stage (N1, 29.91% vs. 11.59%), mean daily alcohol consumption of approximately ≥2 units (40.63% vs. 22.73%) and administration of concomitant medications (41.03% vs. 52.29%) (p < 0.05, Table 1 and Supplementary Tables 1 and 2).